You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Brazil says Chinese coronavirus vaccine trial can resume after suspension

Brazil allowed resumption of late-stage Brazilian clinical trials for China's Sinovac Covid-19 vaccine, which was suspended due to a study subject's death that was reported in Sao Paulo as a suicide

Coronavirus Vaccine | Coronavirus | Brazil

Reuters  |  BRASILIA 

Covid-19 coronavirus
Representative photo of a vaccine

By Anthony Boadle

BRASILIA (Reuters) - health regulator Anvisa on Wednesday allowed resumption of late-stage Brazilian clinical trials for China's Sinovac COVID-19 vaccine, which had been suspended due to a study subject's death that was registered in Sao Paulo as a suicide.

Brazilian medical institute Butantan said in a statement it would restart trials later on Wednesday.

Brazil's president, Jair Bolsonaro, a longtime critic who has baselessly dismissed the Sinovac vaccine as lacking in credibility, had hailed Monday's suspension as a personal victory.

Bolsonaro reiterated, however, on Wednesday evening that his government would purchase whatever vaccine is approved by Anvisa and the Health Ministry, which could ultimately include the Sinovac vaccine, if approved.

The decision to suspend the trial - one of Sinovac's three large late-stage studies - was criticized by the trial organizers, who said the move had taken them by surprise and that there had been no need to stop the study as the death had no relation to the vaccine.

The suspension further inflamed tensions between Bolsonaro and Sao Paulo Governor Joao Doria, who has pinned his political ambitions on the Chinese vaccine that he aims to roll out in his state as early as January, with or without federal assistance.

Anvisa, in its statement on Wednesday, said the initial information it received about the case, which led to the suspension, had been incomplete and lacked the cause of the "severe adverse event." It has strongly dismissed suggestions the decision could have been politically motivated.

"After evaluating the new data presented by the sponsor ... Anvisa understands that it has sufficient reasons to allow the resumption of vaccination," the agency said.

"It is important to clarify that a suspension does not necessarily mean that the product under investigation does not offer quality, safety or efficacy," Anvisa added.

Sinovac, in a statement said: "We are confident in the safety of the vaccine, fully understand and appreciate Anvisa's strict supervision and timely resumption of the clinical studies."

has one of the world's worst COVID-19 outbreaks, with over 5.7 million confirmed cases and 163,000 deaths related to the disease caused by the novel Bolsonaro has come under fire for his constant dismissal of the virus and its dangers.

On Tuesday, Bolsonaro said Brazilians "must stop being sissies" about the virus, adding: "We are all going to die one day."


(Reporting by Anthony Boadle; Additional reporting by Eduardo Simoes in Sao Paulo, Ricardo Brito in Brasilia and Roxanne Liu in Beijing; Writing by Anthony Boadle and Jamie McGeever; Editing by Bill Berkrot and Peter Cooney)

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, November 12 2020. 06:41 IST